{"meshTagsMajor":["Dendritic Cells","Antigens, CD274"],"meshTags":["Humans","Dendritic Cells","Antigens, CD274","Animals","T-Lymphocytes","Melanoma"],"meshMinor":["Humans","Animals","T-Lymphocytes","Melanoma"],"genes":["anti-PD-L1","BRAF"],"organisms":["6755","10090"],"publicationTypes":["Comment","Journal Article"],"abstract":"Although it is successful for some, most melanoma patients are refractory to T cell checkpoint inhibition. In this issue of Immunity, Merad and colleagues (2016) describe a dendritic-cell-based strategy to heighten the efficacy of therapeutic anti-PD-L1 and BRAF inhibitors in mouse melanoma models.","title":"Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor.","pubmedId":"27096314"}